AN2 Therapeutics, Inc. (ANTX)

In August 2025, AN2 Therapeutics reported second-quarter results that surpassed estimates but discontinued its oral epetraborole program. In November 2025, the company announced a research collaboration with GSK and reported a net loss of $9.4 million in its third-quarter results. In November 2024, TD Cowen downgraded ANTX stock due to Phase 2 trial data. In January 2026, the FDA cleared an IND application for an IIT of epetraborole, and insider stock sales were reported. The stock's 52-week range has been between $1.010 and $1.550, with a one-year change of -21.830%.

There is no information to suggest any seasonality in the demand for AN2 Therapeutics' products or services. Demand is primarily driven by medical necessity and disease prevalence rather than seasonal fluctuations.

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics using its boron chemistry platform. The company is in the Pharmaceuticals & Biotech sector, specifically in the Pharmaceuticals industry, with a pipeline of boron-based compounds for infectious diseases and oncology. Its lead product candidate, epetraborole, is being advanced into a Phase 2 trial for Mycobacterium abscessus lung disease after the oral program for pulmonary MAC NTM lung disease was discontinued.

AN2 Therapeutics, Inc. is headquartered in Menlo Park, California, United States. The provided information does not detail a specific global operational or commercial geographic footprint beyond its U.S. base.

AN2 Therapeutics' brand reputation has been influenced by clinical development progress and strategic decisions. The discontinuation of the oral epetraborole program and the downgrade by TD Cowen could have negatively impacted its standing. Positive developments such as a strong cash position, the strategic shift to other indications, the research collaboration with GSK, and the FDA clearance for an IIT could contribute positively to its reputation.

AN2 Therapeutics has 51 institutional owners and shareholders, collectively holding 8,374,181 shares. Major shareholders include Almitas Capital LLC, Vanguard Group Inc, Pfizer Inc, and Renaissance Technologies Llc. Significant individual and institutional ownership percentages include D Perry Matthew (10.28%), Kabeer Aziz (8.853%), Adjuvant Capital LP (8.662%), Eric Easom (5.533%), and Almitas Capital LLC (5.212%).